* 11 percent of babies born premature in 2010, 1.1 million died * Experts estimate 75 percent could be saved * U.S. rate at 12 pct, fueled by later births, fertility treatments NEW YORK, May 2 (Reuters) - The world's developed countries have seen their average rate of premature births double to 6 percent since 1995, despite efforts to reduce the phenomenon, according to a report released on Wednesday. Worldwide, 15 million of the...

-The United Nations Some 15 million babies worldwide – more than one in ten births – are born too early, according to a new United Nations-backed report, released today, which calls for steps such as ensuring the requisite medicines and equipment and training health staff to promote child survival. “All newborns are vulnerable, but preterm babies are acutely so,” says Secretary General Ban Ki-moon, who wrote the foreword to the report, entitled...

Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines, India’s central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunisation programme in seven of its provinces. Pentavalent vaccine doses, a cocktail of five antigens in a single shot, confers immunity against five paediatric diseases - diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib), with the last one considered particularly...

India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...

India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...